Skip to Content

AirDuo RespiClick Approval History

FDA Approved: Yes (First approved January 27, 2017)
Brand name: AirDuo RespiClick
Generic name: fluticasone propionate and salmeterol
Dosage form: Inhalation Powder
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Asthma, Maintenance

AirDuo RespiClick (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.

Development History and FDA Approval Process for AirDuo RespiClick

DateArticle
Jan 30, 2017Approval Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide